Genialis, a Boston, MA-based medtech company that provides a biomarker discovery platform, raised $13 million in Series A funding to transform the way diseases are diagnosed and treatment decisions are made.
Taiwania Capital and Debiopharm Innovation Fund co-led the round. The previous investors First Star Ventures, Redalpine Venture Partners, and Pikas also participated, together with P5 Health Ventures and several angels. Ita Lu of Taiwania and Hamzeh Abdul-Hadi of Debiopharm will join Genialis’ Board of Directors.
The fresh funds will be used to expand its proprietary ResponderID™ platform and build out its comprehensive collection of clinically validated biomarker models to provide pinpoint diagnoses for virtually every cancer patient.
The company wants to propel drug development, diagnostics, and treatment planning through its platform, ResponderID. The company is also investing in R&D collaborations with several leading cancer centers, hospital groups, and clinical academic labs.
ResponderID is an AI/ML-enabled platform with a biology-first approach for clinical and translational research. It yields new biomarkers for drug development and discovery programs, as well as diagnostic tests.
“With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We chose to focus initially on biomarkers that improve the efficiency of drug development, that ensure the right patient gets the right medicine, and make an impact on real people’s lives in a shorter period of time.”
To date, Genialis has used ResponderID in collaboration with biopharma to analyze clinical trial data and inform future trial designs for numerous investigational drugs. Genialis also supports the commercialization of next-gen biomarker assays with several leading diagnostic firms.
Company: Genialis, Inc.
Raised: $13.0M
Round: Series A
Funding Month: March 2023
Lead Investors: Taiwania Capital and Debiopharm Innovation Fund
Additional Investors: First Star Ventures, Redalpine Venture Partners, Pikas, and P5 Health Ventures
Company Website: https://www.genialis.com/
Software Category: Biomarker Discovery Platform
About the Company: Founded in 2015 and led by Rafael Rosengarten and Miha Stajdohar, Genialis is a computational precision medicine company that develops next-generation patient classifiers using machine learning and high-throughput omics data to capture underlying disease biology and predict how patients will likely respond to targeted therapies. Our method is to leverage biomedical data and advanced analytics to help pharma companies develop more effective drugs with a higher probability of clinical success, and diagnostics companies to deploy tests that lead to better treatment decisions. The company is currently based in Boston, US, and Ljubljana, Slovenia, and is trusted by pharma and diagnostics partners. Genialis' mission is to deliver benefits and hopes to patients and their families.
Source: https://www.genialis.com/2023/03/29/genialis-raises-13m-to-build-clinical-biomarkers-that-predict-patient-response/